References
- Starenki D, Hong SK, Wu PK, Park JI. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. Cancer Biol Ther. 2017;18(7):473–483. May 5:0. doi: 10.1080/15384047.2017.1323594
- Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64–71. doi: 10.1016/S2213-8587(15)00337-X.
- Drugs to avoid: Oncology-Haematology. Prescrire Int. 2016;25(170):108–109
- Caprelsa 10 November 2016 EMA/CHMP/199988/2016 Assesment Report http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002315/WC500221415.pdf
- EMA-CHMP ‘ Public assessment report for Cometriq. EMEA/H/C/002640/000’ 19 December 2013: 107 pages. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002640/WC500163705.pdf.
- US FDA – CDER ‘Application number:203756Orig1s000. Medical review(s). Cometriq’ 4 January 2013:114 pages. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203756orig1s000medr.pdf.
- Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissi MC et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639–46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864
- Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16(3):225–238. doi: 10.1016/j.stem.2015.02.015
- Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 2015;6(13):10697–10711
- Lyakhovich A, Leonart ME. Bypassing mechanisms of mitochondria-mediated cancer stem cells resistance to chemo- and radiotherapy. Oxid Med Cell Longev. 2016;2016:1716341. doi: 10.1155/2016/1716341
- Loureiro R, Mesquita KA, Oliveira PJ, Vega-Naredo I. Mitochondria in cancer stem cells: a target for therapy. Recent Pat Endocr Metab Immune Drug Discov. 2013;7:102–114
- López-Erauskin J, Galino J, Ruiz M, Cuezva JM, Fabregat I, Cacabelos D, Boada J, Martínez J, Ferrer I, Pamplona R, et al. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum Mol Genetics. 2013;22(16):3296–3305. doi: 10.1093/hmg/ddt186
- Shen YA, Wang CY, Hsieh YT, Chen YJ, Wei YH. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle. 2015;14(1):86–-98. doi: 10.4161/15384101.2014.974419.
- Benz CC, Yau C. Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev Cancer. 2008;8(11):875–879. doi: 10.1038/nrc2522.